ArticleFrontiers in pharmacology2021
Prediction of the Drug-Drug Interaction Types with the Unified Embedding Features from Drug Similarity Networks.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Multi-GraphDDI: Multi-Feature Fusion and Interaction for Graph-Based Drug-Drug Interaction Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Machine learning and deep learning-based drug-drug interactions prediction: a systematic review focused on anticancer drugs.NPJ precision oncology · 2026Article
- Enabling Drug-Drug Interaction Event Prediction with Multi-view-enhanced Chemical Structural Information.Interdisciplinary sciences, computational life sciences · 2026Article
- DisenKGE-DDI: A Knowledge Graph Embedding Framework Based on Disentangled Graph Attention Networks for Drug-Drug Interaction Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Machine learning models for drug-drug interaction prediction from computational discovery to clinical application.NPJ digital medicine · 2026Review
- AΙ-Driven Drug Repurposing: Applications and Challenges.Medicines (Basel, Switzerland) · 2025Review
- PS3N: leveraging protein sequence-structure similarity for novel drug-drug interaction discovery.Scientific reports · 2025Article
- LLM-Enhanced Multimodal Framework for Drug-Drug Interaction Prediction.Biomedicines · 2025Article
- RCAN-DDI: Relation-aware cross adversarial network for drug-drug interaction prediction.Journal of pharmaceutical analysis · 2025Article
- A comprehensive review of deep learning-based approaches for drug-drug interaction prediction.Briefings in functional genomics · 2025Review
- Mechanisms and therapeutic strategies to reveal and overcome T-cell dysfunction in gastric cancer: translation from basic research to clinical application.Frontiers in immunology · 2025Review
- Drug-drug interactions prediction based on deep learning and knowledge graph: A review.iScience · 2024Review
- MFDA: Multiview fusion based on dual-level attention for drug interaction prediction.Frontiers in pharmacology · 2022Article
- EFMSDTI: Drug-target interaction prediction based on an efficient fusion of multi-source data.Frontiers in pharmacology · 2022Article
- Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents.Computational and structural biotechnology journal · 2022Review
- Multitype drug interaction prediction based on the deep fusion of drug features and topological relationships.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug combination therapies are a promising strategy to overcome drug resistance and improve the efficacy of monotherapy in cancer, and it has been shown to lead to a decrease in dose-related toxicities. Except the synergistic reaction between drugs, some antagonistic drug-drug interactions (DDIs) exist, which is the main cause of adverse drug events. Precisely predicting the type of DDI is important for both drug development and more effective drug combination therapy applications. Recently, numerous text mining- and machine learning-based methods have been developed for predicting DDIs. All these methods implicitly utilize the feature of drugs from diverse drug-related properties. However, how to integrate these features more efficiently and improve the accuracy of classification is still a challenge. In this paper, we proposed a novel method (called NMDADNN) to predict the DDI types by integrating five drug-related heterogeneous information sources to extract the unified drug mapping features. NMDADNN first constructs the similarity networks by using the Jaccard coefficient and then implements random walk with restart algorithm and positive pointwise mutual information for extracting the topological similarities. After that, five network-based similarities are unified by using a multimodel deep autoencoder. Finally, NMDADNN implements the deep neural network (DNN) on the unified drug feature to infer the types of DDIs. In comparison with other recent state-of-the-art DNN-based methods, NMDADNN achieves the best results in terms of accuracy, area under the precision-recall curve, area under the ROC curve, F1 score, precision and recall. In addition, many of the promising types of drug-drug pairs predicted by NMDADNN are also confirmed by using the interactions checker tool. These results demonstrate the effectiveness of our NMDADNN method, indicating that NMDADNN has the great potential for predicting DDI types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.